Niraj Mehta, MD
Radiation Oncology · Pembroke Pines, FLNPI 1598919243
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.2%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Novocure Inc. at 36.2% of the total. Reporting peaked in 2021 at $7,293 and has fallen 83.8% since, to $1,181 in 2025. Among radiation oncology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 266 payments — averaging $61.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$6K
- Myriad Genetic Laboratories, Inc.$2K
- Painteq LLC$2K
- Johnson & Johnson$1K
- Pfizer$555
- Isoray, Inc$547
- plus $4K from 32 others
Across 4 payments — averaging $5250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$21K
What the payments were for
- Consulting fees$5,07531%
- Speaking & faculty fees$1,2007%
- Food & beverage$9,56458%
- Education$6024%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 19 | $5,953 |
| Myriad Genetic Laboratories, Inc. | 29 | $2,252 |
| Painteq LLC | 6 | $1,852 |
| Johnson & Johnson | 63 | $1,464 |
| Pfizer | 25 | $555 |
| Isoray, Inc | 7 | $547 |
| Sumitomo Pharma America, Inc. | 20 | $520 |
| Boston Scientific | 18 | $496 |
| Astellas Pharma US Inc | 10 | $470 |
| Brainlab, Inc. | 6 | $318 |
| Myovant Sciences Inc. | 15 | $252 |
| Reflexion Medical, Inc. | 2 | $194 |
| Bayer | 7 | $183 |
| AbbVie | 4 | $172 |
| Daiichi Sankyo Inc. | 1 | $123 |
| Idorsia Pharmaceuticals US Inc | 1 | $122 |
| Teleflex LLC | 2 | $87 |
| Telix Pharmaceuticals | 3 | $85 |
| Palette Life Sciences, Inc. | 2 | $81 |
| Blue Earth Diagnostics | 3 | $68 |
| AstraZeneca | 2 | $65 |
| Novo Nordisk | 1 | $65 |
| Cashflow Solutions, LLC | 3 | $60 |
| Bioprotect Medical, Inc. | 2 | $46 |
| Coloplast | 1 | $45 |
| Accuray Incorporated | 1 | $44 |
| Novartis | 2 | $42 |
| Napo Pharmaceuticals Inc | 1 | $36 |
| Merck | 1 | $32 |
| Foundation Medicine, Inc. | 1 | $31 |
| Karyopharm Therapeutics Inc. | 1 | $27 |
| Dendreon Pharmaceuticals LLC | 1 | $26 |
| Progenics Pharmaceuticals, Inc. | 1 | $25 |
| Verity Pharmaceuticals Inc. | 1 | $23 |
| Axonics, Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Tactile Systems Technology Inc | 1 | $20 |
| Q Biomed Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PAINTEQ$1,852
- Prolaris$1,575
- Brachytherapy Source$407
- Optune$385
- REFLEXION MEDICAL RADIOTHERAPY SYSTEM$156
- OPTUNE LUA (NOVOTTF-200T)$151
- Enhertu$123
- QUVIVIQ$122
- Oncology$115
How this compares
$16,441 in reported general payments places this provider in the 90th percentile of 465 radiation oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 36 | $558,662 |
| Lupron DepotLeuprolide Acetate | 67 | $400,220 |
| XtandiEnzalutamide | 28 | $398,819 |
| OrgovyxRelugolix | 116 | $318,139 |
| EligardLeuprolide Acetate | 20 | $26,182 |
| MyrbetriqMirabegron | 16 | $7,143 |
| Solifenacin Succinate | 12 | $562 |
| Bicalutamide | 13 | $556 |
| Tamsulosin Hcl | 95 | $514 |
| Triamcinolone Acetonide | 13 | $115 |
| Sildenafil Citrate | 18 | $62 |
| Lorazepam | 12 | $8 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $1,464 | $558,66236 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $470 | $405,96244 claims |
| AbbVieLupron Depot | $172 | $400,22067 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $520 | $318,139116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 465 radiation oncology providers in Florida.
Other radiation oncology in Pembroke Pines
- Shravan KandulaOrlando$444K
- Martin KeischMiami Shores$319K
- Marcio FagundesMiami$274K
- Evan ThomasWinter Park$209K
- Rupesh KotechaMiami$208K
- John SylvesterLakewood Ranch$205K
- Ravi ShridharOrlando$192K
- Alan BrownFort Myers$165K
- Akash NandaOrlando$165K
- Michael ChuongMiami$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.